Regeneron Pharmaceuticals Inc

Company Profile

Regeneron Pharmaceuticals Inc had its IPO on 1991-04-02 under the ticker symbol REGN.

The company operates in the Healthcare sector and Biotechnology industry. Regeneron Pharmaceuticals Inc has a staff strength of 12,099 employees.

Stock update

Shares of Regeneron Pharmaceuticals Inc opened at $730.31 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $724.12 - $740.18, and closed at $739.95.

This is a +1.2% increase from the previous day's closing price.

A total volume of 527,300 shares were traded at the close of the day’s session.

In the last one week, shares of Regeneron Pharmaceuticals Inc have increased by +0.35%.

Regeneron Pharmaceuticals Inc's Key Ratios

Regeneron Pharmaceuticals Inc has a market cap of $81.18 billion, indicating a price to book ratio of 3.8097 and a price to sales ratio of 5.8086.

In the last 12-months Regeneron Pharmaceuticals Inc’s revenue was $12.37 billion with a gross profit of $7.02 billion and an EBITDA of $5.08 billion. The EBITDA ratio measures Regeneron Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Regeneron Pharmaceuticals Inc’s operating margin was 38.08% while its return on assets stood at 10.44% with a return of equity of 19.27%.

In Q1, Regeneron Pharmaceuticals Inc’s quarterly earnings growth was a negative -16.7% while revenue growth was a positive 6.6%.

Regeneron Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

17.7936

Trailing PE

19.9987

PEG

9.0135

Its diluted EPS in the last 12-months stands at $37 per share while it has a forward price to earnings multiple of 17.7936 and a PEG multiple of 9.0135. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Regeneron Pharmaceuticals Inc’s profitability.

Regeneron Pharmaceuticals Inc stock is trading at a EV to sales ratio of 5.6422 and a EV to EBITDA ratio of 12.0691. Its price to sales ratio in the trailing 12-months stood at 5.8086.

Regeneron Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$30.06 billion

Total Liabilities

$3.10 billion

Operating Cash Flow

$-235700000.00

Capital Expenditure

$279.10 million

Dividend Payout Ratio

0%

Regeneron Pharmaceuticals Inc ended 2023 with $30.06 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $30.06 billion while shareholder equity stood at $23.50 billion.

Regeneron Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $3.10 billion in other current liabilities, 100000.00 in common stock, $24.12 billion in retained earnings and $0 in goodwill. Its cash balance stood at $3.92 billion and cash and short-term investments were $8.96 billion. The company’s total short-term debt was $0 while long-term debt stood at $1.98 billion.

Regeneron Pharmaceuticals Inc’s total current assets stands at $16.91 billion while long-term investments were $6.07 billion and short-term investments were $5.04 billion. Its net receivables were $5.12 billion compared to accounts payable of $599.50 million and inventory worth $1.87 billion.

In 2023, Regeneron Pharmaceuticals Inc's operating cash flow was $-235700000.00 while its capital expenditure stood at $279.10 million.

Comparatively, Regeneron Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$739.95

52-Week High

$837.55

52-Week Low

$538.01

Analyst Target Price

$888.3

Regeneron Pharmaceuticals Inc stock is currently trading at $739.95 per share. It touched a 52-week high of $837.55 and a 52-week low of $837.55. Analysts tracking the stock have a 12-month average target price of $888.3.

Its 50-day moving average was $783.7 and 200-day moving average was $738.18 The short ratio stood at 2.25 indicating a short percent outstanding of 0%.

Around 254.1% of the company’s stock are held by insiders while 8964% are held by institutions.